|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 3/16/20 AVROBIO, Inc. 10-K 12/31/19 85:8.4M ActiveDisclosure/FA |
Document/Exhibit Description Pages Size
1: 10-K Annual Report HTML 1.15M
2: EX-4.3 Instrument Defining the Rights of Security Holders HTML 53K
5: EX-10.16 Material Contract HTML 94K
3: EX-10.7 Material Contract HTML 49K
4: EX-10.8 Material Contract HTML 38K
6: EX-21.1 Subsidiaries List HTML 25K
7: EX-23.1 Consent of Experts or Counsel HTML 30K
8: EX-31.1 Certification -- §302 - SOA'02 HTML 35K
9: EX-31.2 Certification -- §302 - SOA'02 HTML 35K
10: EX-32.1 Certification -- §906 - SOA'02 HTML 30K
17: R1 Document and Entity Information HTML 95K
64: R2 Consolidated Balance Sheets HTML 84K
72: R3 Consolidated Balance Sheets (Parenthetical) HTML 45K
46: R4 Consolidated Statements of Operations and HTML 68K
Comprehensive Loss
18: R5 Consolidated Statements of Redeemable Convertible HTML 100K
Preferred Stock and Stockholders' (Deficit) Equity
65: R6 Consolidated Statements of Redeemable Convertible HTML 30K
Preferred Stock and Stockholders' (Deficit) Equity
(Parenthetical)
73: R7 Consolidated Statements of Cash Flows HTML 108K
45: R8 Nature of the Business HTML 34K
19: R9 Summary of Significant Accounting Policies HTML 106K
84: R10 Fair Value of Financial Assets and Liabilities HTML 123K
61: R11 Prepaid Expenses and Other Current Assets HTML 55K
33: R12 Property and Equipment, Net HTML 54K
41: R13 Accrued Expenses HTML 49K
83: R14 Loan Agreement and Warrant to Purchase Preferred HTML 31K
Stock
60: R15 Redeemable Convertible Preferred Stock HTML 30K
32: R16 Common Stock HTML 64K
40: R17 Stock-Based Compensation HTML 145K
85: R18 License Agreements HTML 50K
59: R19 Income Taxes HTML 126K
22: R20 Net Loss per Share Attributable to Common HTML 47K
Stockholders
48: R21 Commitments and Contingencies HTML 48K
71: R22 Related Party Transactions HTML 32K
63: R23 Benefit Plans HTML 30K
21: R24 Subsequent Events HTML 30K
47: R25 Summary of Significant Accounting Policies HTML 171K
(Policies)
70: R26 Summary of Significant Accounting Policies HTML 50K
(Tables)
62: R27 Fair Value of Financial Assets and Liabilities HTML 123K
(Tables)
20: R28 Prepaid Expenses and Other Current Assets (Tables) HTML 56K
49: R29 Property and Equipment, Net (Tables) HTML 53K
43: R30 Accrued Expenses (Tables) HTML 49K
34: R31 Common Stock (Tables) HTML 64K
56: R32 Stock-Based Compensation (Tables) HTML 139K
81: R33 Income Taxes (Tables) HTML 118K
44: R34 Net Loss per Share Attributable to Common HTML 46K
Stockholders (Tables)
35: R35 Commitments and Contingencies (Tables) HTML 40K
58: R36 Nature of the Business - Additional Information HTML 38K
(Detail)
82: R37 Summary of Significant Accounting Policies - HTML 45K
Additional Information (Detail)
42: R38 Summary of Significant Accounting Policies - HTML 36K
Estimated Useful Lives of Property and Equipment
(Detail)
36: R39 Summary of Significant Accounting Policies - HTML 38K
Statements of cash flows subsequent to the
adoption of ASU (Detail)
51: R40 Fair Value of Financial Assets and Liabilities - HTML 38K
Summary of Financial Assets and Liabilities
Measured at Fair Value on Recurring Basis (Detail)
23: R41 Fair Value of Financial Assets and Liabilities - HTML 43K
Additional Information (Detail)
68: R42 Fair Value of Financial Assets and Liabilities - HTML 36K
Summary of Changes in Fair Value of Preferred
Stock Warrant Liability for Fair Value Determined
by Level 3 Inputs (Detail)
76: R43 Fair Value of Financial Assets and Liabilities - HTML 36K
Summary of Changes in Fair Value of Derivative
Liability for Fair Value Determined by Level 3
Inputs (Detail)
52: R44 Prepaid Expenses and Other Current Assets - HTML 45K
Summary of Prepaid Expenses and Other Current
Assets (Detail)
24: R45 Property and Equipment, Net - Summary of Property HTML 42K
and Equipment, Net (Detail)
69: R46 Property and Equipment, Net - Additional HTML 29K
Information (Detail)
77: R47 Accrued Expenses - Summary of Accrued Expenses HTML 40K
(Detail)
50: R48 Loan Agreement and Warrant to Purchase Preferred HTML 60K
Stock - Additional Information (Detail)
25: R49 Redeemable Convertible Preferred Stock - HTML 60K
Additional Information (Detail)
30: R50 Common Stock - Additional Information (Detail) HTML 62K
38: R51 Common Stock - Summary of Common Stock Reserved HTML 41K
for Future Issuance (Detail)
80: R52 Stock-Based Compensation - Additional Information HTML 72K
(Detail)
55: R53 Stock-Based Compensation - Summary of Assumptions HTML 35K
that Used to Determine Grant-Date Fair Value of
Stock Options Granted to Employees and Members of
Board (Detail)
29: R54 Stock-Based Compensation - Summary of Stock Option HTML 64K
Activity (Detail)
37: R55 Stock-Based Compensation - Summary of Restricted HTML 43K
Stock Unit Activity (Detail)
79: R56 Stock-Based Compensation - Schedule of Stock-based HTML 34K
Compensation Expense (Detail)
54: R57 License Agreements - Additional Information HTML 91K
(Detail)
28: R58 Income Taxes - Additional Information (Detail) HTML 76K
39: R59 Income Taxes - Schedule of Reconciliation of HTML 54K
Income Tax Expense (Benefit) (Detail)
75: R60 Income Taxes - Schedule of Deferred Tax Assets and HTML 57K
Liabilities (Detail)
67: R61 Net Loss per Share Attributable to Common HTML 33K
Stockholders - Schedule of Dilutive Common Stock
Equivalents Excluded from Computation of Diluted
Net Loss per Share (Detail)
27: R62 Commitments and Contingencies - Additional HTML 41K
Information (Detail)
53: R63 Commitments and Contingencies - Schedule Of Future HTML 40K
Minimum Rental Payment Under Operating Lease
(Detail)
74: R64 Related Party Transactions - Additional HTML 47K
information (Detail)
66: R65 Benefit Plans - Additional Information (Detail) HTML 30K
26: R66 Subsequent Events - Additional Information HTML 43K
(Detail)
31: XML IDEA XML File -- Filing Summary XML 150K
57: EXCEL IDEA Workbook of Financial Reports XLSX 87K
11: EX-101.INS XBRL Instance -- avro-20191231 XML 1.75M
13: EX-101.CAL XBRL Calculations -- avro-20191231_cal XML 142K
14: EX-101.DEF XBRL Definitions -- avro-20191231_def XML 475K
15: EX-101.LAB XBRL Labels -- avro-20191231_lab XML 1.21M
16: EX-101.PRE XBRL Presentations -- avro-20191231_pre XML 901K
12: EX-101.SCH XBRL Schema -- avro-20191231 XSD 185K
78: ZIP XBRL Zipped Folder -- 0001564590-20-011144-xbrl Zip 149K
Exhibit 10.8
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM IF PUBLICLY DISCLOSED.
AMENDMENT NO. 2 TO LICENSE AGREEMENT
This AMENDMENT NO. 2 TO LICENSE AGREEMENT (herein referred to as “Amendment No. 2”) is made and entered into as of this 7th day of January, 2020 (the “Amendment No. 2 Effective Date”), between BioMarin Pharmaceutical Inc., a Delaware corporation, with offices at 770 Lindaro Street, San Rafael, CA 94901 (“BioMarin”), and AVROBIO, Inc., a Delaware corporation having a place of business at One Kendall Square, Building 300, Suite 201, Cambridge, MA 02139 (“AVROBIO”). Each of BioMarin and “AVROBIO” may be referred to herein as a “Party” or collectively as the “Parties.”
|
1. |
This Amendment No. 2 shall serve as an amendment to that certain License Agreement, effective as of August 31, 2017 and amended effective as of February 21, 2018 by and between AVROBIO and BioMarin (the “Original Agreement”). Except as expressly modified hereby, the Original Agreement shall continue in full force according to its terms. Capitalized terms not otherwise defined in this Amendment No. 2 shall have the meaning ascribed to such term in the Original Agreement. |
|
2. |
AVROBIO’s address set forth in the introductory paragraph of the Original Agreement and in Section 11.4 of the Original Agreement is hereby deleted in its entirety and replaced with the AVROBIO address set forth above in the introductory paragraph of this Amendment No. 2. |
|
3. |
Section 2.1.2 of the Original Agreement is hereby deleted and replaced with the following: |
“2.1.2Subject to the terms and conditions of this Agreement, BioMarin hereby grants to AVROBIO a limited, non-sublicensable, non-transferable, non-exclusive license to use [***] solely for the experiments set forth in Schedule D, which shall be performed by AVROBIO personnel or by a permitted Third Party at the facilities expressly specified therein. With BioMarin’s prior written consent, AVROBIO may subcontract the performance of certain experiments set forth in Schedule D to additional Third Parties, including consultants. With respect to each and any such Third Party (a) such Third Party shall be bound by obligations consistent with AVROBIO’s obligations set forth in Sections 2.6.2, 2.6.5, 2.6.7, and 7 of this Agreement; and (b) AVROBIO shall remain liable for such permitted Third Party’s performance.”
|
4. |
Section 2.6.1 of the Original Agreement is hereby deleted and replaced with the following: |
“2.6.1BioMarin agrees to supply AVROBIO, and/or any permitted Third Party as directed by AVROBIO, with [***] in the amount set forth in Schedule D hereto.”
|
5. |
As of the Amendment No. 2 Effective Date, Schedule D attached to the Original Agreement is replaced in its entirety with a new Schedule D, in the form attached to this Amendment No. 2 as Attachment 1. |
|
6. |
This Amendment No. 2 shall inure to the benefit of and be binding upon the Parties hereto and their respective heirs, successors, trustees, transferees and assigns. |
|
7. |
This Amendment No. 2 may be executed in any number of counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. |
[Signature page follows]
|
7. |
1
IN WITNESS WHEREOF, the Parties hereto, intending to be legally bound hereby, have caused this Amendment No. 2 to be executed and delivered by their proper and duly authorized officers effective as of the day and year first above written.
|
BioMarin Pharmaceutical Inc. |
|
AVROBIO, Inc. |
||
|
|
|
|
|
|
|
|
/s/ Geoff MacKay |
|||
|
|
|
|
|
|
|
By: |
|
By: |
||
|
|
|
|
|
|
|
Its: |
Group Vice President |
|
Its: |
CEO |
|
|
08-Jan-2020 |
|
|
08-Jan-2020 |
2
Schedule D
[***]
3
| This ‘10-K’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed on: | 3/16/20 | 8-K, S-8 | ||
| For Period end: | 12/31/19 | 5 | ||
| 2/21/18 | ||||
| 8/31/17 | ||||
| List all Filings | ||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 4/15/24 AVROBIO, Inc. S-4/A 91:17M Donnelley … Solutions/FA 3/26/24 AVROBIO, Inc. S-4/A 3/25/24 89:18M Donnelley … Solutions/FA 3/14/24 AVROBIO, Inc. 10-K 12/31/23 80:9.4M Donnelley … Solutions/FA 2/14/24 AVROBIO, Inc. S-4 91:25M Donnelley … Solutions/FA 3/23/23 AVROBIO, Inc. 10-K 12/31/22 82:10M Donnelley … Solutions/FA 11/08/22 AVROBIO, Inc. S-3 8:1.8M Broadridge Fin’l So… Inc 3/17/22 AVROBIO, Inc. 10-K 12/31/21 78:9.1M ActiveDisclosure/FA 3/18/21 AVROBIO, Inc. 10-K 12/31/20 73:9.1M ActiveDisclosure/FA 11/20/20 AVROBIO, Inc. 424B5 1:5.2M Donnelley … Solutions/FA 11/19/20 AVROBIO, Inc. 424B5 1:5.1M Donnelley … Solutions/FA |